Latest Period
Q1 2026
Security Snapshot
Agomab Therapeutics NV - American Depositary Shares, each representing one common share, no nominal value per share (AGMB) Institutional Ownership
CUSIP: 00860C102
13F Institutional Holders and Ownership History for Q1 2026
Institutions Reporting
32
Shares (Excl. Options)
23,354,227
Price
$10.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American Depositary Shares, each representing one common share, no nominal value per share
- Symbol
- AGMB on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 23,354,227
- Total 13F value
- $245,296,936
- Portfolio coverage rank
- 0%
- Share change
- +23,354,227
- Value change
- +$245,296,936
- Number of holders
- 32
- Shares outstanding
- 49,208,543
- SEC-reported price per share
- $12.08
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AGMB - Agomab Therapeutics NV - American Depositary Shares, each representing one common share, no nominal value per share is tracked under CUSIP 00860C102.
- 32 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q1 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 32 institutions filings for Q1 2026.
Security key
00860C102
Latest holder period
Q1 2026
13F holders
32
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
AGMB full holder history
Agomab Therapeutics NV SEC filings
Agomab Therapeutics NV company facts
Agomab Therapeutics NV insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00860C102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AGMB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 11% | 5,141,992 | LSP 7 Cooperatieve U.A. | 09 Feb 2026 | ||||
| Sanofi | 5.7% | $28,415,410 | 2,783,096 | SANOFI | 31 Mar 2026 | |||
| Cormorant Asset Management, LP | 5% | $25,171,203 | 2,465,348 | Cormorant Asset Management, LP | 31 Mar 2026 |
As of 31 Mar 2026, 32 institutional investors reported holding 23,354,227 shares of Agomab Therapeutics NV - American Depositary Shares, each representing one common share, no nominal value per share (AGMB). This represents 47% of the company’s total 49,208,543 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
47%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 10% | 5,141,992 | 5.3% | $53,939,496 | |
| Sanofi | 5.7% | 2,783,096 | 8.7% | $29,194,677 | |
| Cormorant Asset Management, LP | 5% | 2,465,348 | 1.3% | $25,861,501 | |
| TCG Crossover Management, LLC | 4.2% | 2,053,233 | 0.62% | $21,538,414 | |
| FEDERATED HERMES, INC. | 3.3% | 1,618,000 | 0.03% | $16,972,820 | |
| Casdin Capital, LLC | 3.1% | 1,550,000 | 1.2% | $16,259,500 | |
| ANDERA PARTNERS | 3.1% | 1,538,702 | 9.1% | $16,140,984 | |
| FMR LLC | 3% | 1,458,677 | 0% | $15,301,522 | |
| Nantahala Capital Management, LLC | 2.4% | 1,200,000 | 0.8% | $12,852,000 | |
| Aberdeen Group plc | 1.4% | 707,656 | 0.01% | $7,423,311 | |
| PERCEPTIVE ADVISORS LLC | 1.2% | 600,000 | 0.12% | $6,294,000 | |
| SAMSARA BIOCAPITAL, LLC | 1.2% | 600,000 | 0.61% | $6,294,000 | |
| Siren, L.L.C. | 0.84% | 411,250 | 0.12% | $4,314,013 | |
| LMR Partners LLP | 0.61% | 300,000 | 0.03% | $3,147,000 | |
| SEVEN GRAND MANAGERS, LLC | 0.41% | 200,000 | 0.14% | $2,098,000 | |
| Redmile Group, LLC | 0.32% | 156,250 | 0.11% | $1,639,063 | |
| MILLENNIUM MANAGEMENT LLC | 0.19% | 95,233 | 0% | $998,994 | |
| Pfizer Inc | 0.15% | 75,000 | 0.34% | $813,750 | |
| Alyeska Investment Group, L.P. | 0.15% | 75,000 | 0% | $786,750 | |
| Laurion Capital Management LP | 0.1% | 50,000 | 0.05% | $524,500 | |
| Bellevue Group AG | 0.1% | 50,000 | 0.01% | $524,500 | |
| SECTORAL ASSET MANAGEMENT INC | 0.09% | 43,500 | 0.4% | $477,295 | |
| GOLDMAN SACHS GROUP INC | 0.07% | 35,739 | 0% | $374,902 | |
| Burkehill Global Management, LP | 0.07% | 35,000 | 0.02% | $367,150 | |
| CITADEL ADVISORS LLC | 0.07% | 35,000 | 0% | $367,150 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q1 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 23,354,227 | $245,296,936 | +$245,296,936 | $10.49 | 32 |